Skip to Content

Ethinyl estradiol / norelgestromin Pregnancy and Breastfeeding Warnings

Ethinyl estradiol / norelgestromin is also known as: Ortho Evra, Xulane

Ethinyl estradiol / norelgestromin Pregnancy Warnings

Use is contraindicated. US FDA pregnancy category: Not formally assigned to a pregnancy category. Comments: -Discontinue use if pregnancy is confirmed. -Avoid administration to induce withdrawal bleeding as a test for pregnancy. -Avoid administration during pregnancy to treat threatened or habitual abortion. -Increased risk of venous thromboembolism during the postpartum period should be considered when restarting this drug.

Epidemiological data have failed to reveal an increased risk of genital or nongenital birth defects when this drug was taken before pregnancy nor evidence of teratogenicity when used inadvertently in early pregnancy. There are no controlled data in human pregnancy.

See references

Ethinyl estradiol / norelgestromin Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug. Excreted into human milk: Yes Comments: -Other forms of contraception should be used until the child is completely weaned. -Small amounts of contraceptive steroids/metabolites are present in breast milk. -Postpartum women who are breastfeeding should not use combined hormonal contraceptives during the first 3 weeks after delivery due increased risk for venous thromboembolism. -Postpartum women who are breastfeeding with other risk factors for venous thromboembolism should not use combined hormonal contraceptives 4 to 6 weeks after delivery. -Nursing mothers should not use combined hormonal contraceptives during the fourth week postpartum due to the potential to adversely affect the milk supply. -The World Health Organization suggest that combined oral contraceptives should not be used in nursing mothers before 42 days postpartum and the disadvantages of using the method generally outweigh the advantages between 6 weeks and 6 months postpartum.

Combined hormonal contraceptives have been known to reduce milk production and change the composition of breast milk.

See references

References for pregnancy information

  1. "Product Information. Ortho Evra (ethinyl estradiol-norelgestromin)." Janssen Pharmaceuticals, Titusville, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Ortho Evra (ethinyl estradiol-norelgestromin)." Janssen Pharmaceuticals, Titusville, NJ.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.